Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hocher, B.
Right arrow Articles by Paul, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hocher, B.
Right arrow Articles by Paul, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2000) 15: 935-937
© 2000 European Renal Association-European Dialysis and Transplant Association


Editorial Comments

Transgenic animal models for the analysis of the renal endothelin system

Berthold Hocher1 and Martin Paul2,

1 Department of Nephrology, University Hospital Charité, Humboldt Universität zu Berlin and 2 Institute of Clinical Pharmacology and Toxicology, Benjamin Franklin Medical Center, Freie Universität Berlin, Berlin, Germany

The endothelin types

Endogenous peptidergic factors with vasoactive properties were first described by Hickey et al. in 1985 [1]. Yanagisawa and co-workers found that porcine endothelial cells generated a 21-aminoacid peptide, endothelin-1 in 1988 [2]. An i.v. injection of this new endothelium-derived peptide revealed that endothelin-1 (ET-1) is one of the most potent vasoconstrictors in vivo. Two further members of the ET family were described later and termed ET-2 and ET-3. Most studies on the ET system have focused on ET-1. Release of the active ET-1 peptide requires cleavage of a Trp21–Val22 bond in the carboxy terminal of the precursor molecule, big ET-1. This reaction is catalysed by a membrane-bound metalloprotease, ET-converting enzyme (ECE-1). ET synthesis is mainly regulated on the level of gene transcription when vasoconstrictor peptides, inflammatory cytokines, and physical factors (e.g. hypoxia and shear stress) act on the endothelium.

Endothelin and the kidney

Although the normal human kidney . . . [Full Text of this Article]

The transgenic animal models

The knock-out animal models

What are the conclusions?

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
P. Boor, K. Sebekova, T. Ostendorf, and J. Floege
Treatment targets in renal fibrosis
Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3391 - 3407.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
B. Kiperova
The treatment of glomerular disease--a compromise between the standard and the individual approach
Nephrol. Dial. Transplant., July 1, 2003; 18(90005): v31 - 33.
[Abstract] [Full Text] [PDF]